Thr57
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr57  -  EEF2 (human)

Site Information
rAGEtRFtDtRkDEQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448040
Associated spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 83 ) , mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 19 , 20 , 21 , 22 , 23 , 25 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 42 , 43 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 58 , 59 , 60 , 61 , 62 , 64 , 66 , 67 , 69 , 70 , 71 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 84 ) , mutation of modification site ( 41 ) , phospho-antibody ( 1 , 7 , 26 , 41 , 44 , 63 , 65 , 68 , 72 , 82 , 83 , 85 , 86 , 87 ) , western blotting ( 1 , 7 , 26 , 41 , 44 , 63 , 65 , 68 , 72 , 82 , 85 , 86 , 87 )
Disease tissue studied:
bone cancer ( 26 ) , breast cancer ( 5 , 10 , 20 , 21 , 70 ) , breast ductal carcinoma ( 10 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 , 70 ) , breast cancer, triple negative ( 3 , 10 ) , cervical cancer ( 55 , 68 , 85 , 86 ) , cervical adenocarcinoma ( 55 ) , cervical squamous cell carcinoma ( 68 , 85 , 86 ) , gastric cancer ( 73 ) , gastric carcinoma ( 73 ) , leukemia ( 25 , 27 , 74 , 77 , 78 ) , acute myelogenous leukemia ( 25 ) , chronic myelogenous leukemia ( 74 , 77 , 78 ) , T cell leukemia ( 27 ) , hepatocellular carcinoma, surrounding tissue ( 51 ) , liver cancer, surrounding tissue ( 54 ) , lung cancer ( 14 , 21 , 58 , 59 , 60 , 61 , 69 , 75 , 76 ) , non-small cell lung cancer ( 21 , 58 , 59 , 60 , 61 , 69 , 75 , 76 ) , non-small cell lung adenocarcinoma ( 14 , 58 , 75 ) , non-small cell squamous cell lung carcinoma ( 75 ) , lymphoma ( 41 ) , B cell lymphoma ( 41 ) , neuroblastoma ( 44 ) , ovarian cancer ( 10 ) , pancreatic ductal adenocarcinoma ( 13 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 63 , 65 , 82 ) , 'pancreatic, ductal'-pancreas ( 13 ) , 293 (epithelial) ( 45 , 46 , 47 , 48 , 62 , 68 ) , 293T (epithelial) ( 6 , 81 ) , A549 (pulmonary) ( 15 ) , breast ( 3 , 10 , 70 ) , BT-20 (breast cell) ( 21 ) , BT-474 (breast cell) ( 5 ) , BT-549 (breast cell) ( 21 ) , Calu 6 (pulmonary) ( 21 ) , DT40 (B lymphocyte) ( 41 ) , endothelial-aorta ( 22 ) , Flp-In T-Rex-293 (epithelial) ( 23 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 23 ) , GM00130 (B lymphocyte) ( 49 ) , H2009 (pulmonary) ( 21 ) , H2077 (pulmonary) ( 21 ) , H2887 (pulmonary) ( 21 ) , H322 (pulmonary) ( 21 ) , H322M (pulmonary) ( 21 ) , HCC1359 (pulmonary) ( 21 ) , HCC1937 (breast cell) ( 21 ) , HCC2279 (pulmonary) ( 21 ) , HCC366 (pulmonary) ( 21 ) , HCC4006 (pulmonary) ( 21 ) , HCC78 (pulmonary) ( 21 ) , HeLa (cervical) ( 2 , 8 , 19 , 43 , 56 , 66 , 67 , 68 , 83 , 87 ) , HeLa S3 (cervical) ( 55 ) , hepatocyte-liver ( 51 ) , HOP62 (pulmonary) ( 21 ) , HT-29 (intestinal) ( 84 ) , HUES-9 ('stem, embryonic') ( 42 ) , Jurkat (T lymphocyte) ( 16 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 50 , 52 , 53 , 64 , 71 , 79 , 80 ) , K562 (erythroid) ( 19 , 56 , 74 , 77 , 78 ) , KB (squamous) ( 68 , 85 , 86 ) , KG-1 (myeloid) ( 25 ) , Kit225 (T lymphocyte) ( 27 ) , liver ( 12 , 54 ) , LOU-NH91 (squamous) ( 21 ) , lung ( 14 , 69 ) , MCF-7 (breast cell) ( 5 , 21 ) , MCF10A1 (epithelial) ( 1 ) , MDA-MB-231 (breast cell) ( 21 ) , MDA-MB-468 (breast cell) ( 21 ) , MEF (fibroblast) ( 68 ) , MKN-45 (gastric) ( 73 ) , myocyte-heart ( 86 ) , NCI-H1395 (pulmonary) ( 21 ) , NCI-H1568 (pulmonary) ( 21 ) , NCI-H157 (pulmonary) ( 21 ) , NCI-H1648 (pulmonary) ( 21 ) , NCI-H1650 (pulmonary) ( 59 , 60 , 61 ) , NCI-H1666 (pulmonary) ( 21 ) , NCI-H1703 (squamous) ( 75 ) , NCI-H2030 (pulmonary) ( 21 ) , NCI-H2172 (pulmonary) ( 21 ) , NCI-H2228 (pulmonary) ( 58 ) , NCI-H3255 (pulmonary) ( 76 ) , NCI-H460 (pulmonary) ( 21 ) , NCI-H520 (squamous) ( 21 ) , NCI-H647 (pulmonary) ( 21 ) , oocyte ( 72 ) , ovarian ( 72 ) , ovary ( 10 ) , PC9 (pulmonary) ( 21 ) , SH-SY5Y (neural crest) ( 11 , 44 ) , SKBr3 (breast cell) ( 20 ) , U2OS (bone cell) ( 26 )

Upstream Regulation
Regulatory protein:
ChaK1 (human) ( 41 ) , GSK3A (human) ( 44 ) , GSK3B (human) ( 44 )
Putative in vivo kinases:
EEF2K (human) ( 1 )
Kinases, in vitro:
EEF2K (human) ( 1 )
Treatments:
2-deoxyglucose ( 7 , 85 , 86 ) , acadesine ( 86 ) , adriamycin ( 26 ) , anisomycin ( 87 ) , BIO ( 44 ) , carbamazepine ( 44 ) , CCCP ( 86 ) , compound_C ( 26 ) , exercise ( 63 , 82 ) , glucose_starvation ( 44 ) , insulin ( 65 , 85 ) , ionizing_radiation ( 26 ) , IP(3) ( 44 ) , ischemia ( 10 ) , JAN-978 ( 7 ) , lithium ( 44 ) , LRRK2-IN-1 ( 11 ) , metformin ( 72 ) , Mg(+2) ( 41 ) , MG132 ( 26 ) , peptide inhibitor ( 44 ) , rapamycin ( 85 , 86 ) , SB203580 ( 86 , 87 ) , SB216763 ( 44 ) , seliciclib ( 68 ) , serum_withdrawal ( 44 ) , TDZD-8 ( 44 ) , TNF ( 87 ) , U0126 ( 83 , 85 ) , valproic_acid ( 44 ) , wortmannin ( 85 )

Downstream Regulation
Effects of modification on EEF2:
phosphorylation ( 41 )
Effects of modification on biological processes:
translation, altered ( 63 )

References 

1

Will N, et al. (2018) Structural Dynamics of the Activation of Elongation Factor 2 Kinase by Ca-Calmodulin. J Mol Biol
29800565   Curated Info

2

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

5

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

6

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

7

Wang X, et al. (2015) Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity. Biochem J 467, 321-31
25670349   Curated Info

8

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

9

Tavares CD, et al. (2014) The molecular mechanism of eukaryotic elongation factor 2 kinase activation. J Biol Chem 289, 23901-16
25012662   Curated Info

10

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

11

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

12

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

13

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

14

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

15

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

16

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

17

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

18

Hizli AA, et al. (2013) Phosphorylation of eukaryotic elongation factor 2 (eEF2) by cyclin A-cyclin-dependent kinase 2 regulates its inhibition by eEF2 kinase. Mol Cell Biol 33, 596-604
23184662   Curated Info

19

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

20

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

21

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

22

Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81
22497526   Curated Info

23

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

24

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

25

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

26

Kruiswijk F, et al. (2012) Coupled Activation and Degradation of eEF2K Regulates Protein Synthesis in Response to Genotoxic Stress. Sci Signal 5, ra40
22669845   Curated Info

27

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info

28

Mulhern D (2011) CST Curation Set: 13068; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F
Curated Info

29

Mulhern D (2011) CST Curation Set: 13072; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

30

Guo A (2011) CST Curation Set: 12436; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

31

Mulhern D (2011) CST Curation Set: 12398; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

32

Guo A (2011) CST Curation Set: 12077; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738
Curated Info

33

Guo A (2011) CST Curation Set: 12078; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738
Curated Info

34

Guo A (2011) CST Curation Set: 12059; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

35

Guo A (2011) CST Curation Set: 12060; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

36

Guo A (2011) CST Curation Set: 12063; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

37

Guo A (2011) CST Curation Set: 11846; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

38

Guo A (2011) CST Curation Set: 11848; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

39

Guo A (2011) CST Curation Set: 11849; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738
Curated Info

40

Guo A (2011) CST Curation Set: 11850; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

41

Perraud AL, Zhao X, Ryazanov AG, Schmitz C (2011) The channel-kinase TRPM7 regulates phosphorylation of the translational factor eEF2 via eEF2-k. Cell Signal 23, 586-93
21112387   Curated Info

42

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

43

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

44

Karyo R, et al. (2010) Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Mol Cell Neurosci 45, 449-55
20708687   Curated Info

45

Guo A (2010) CST Curation Set: 6258; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

46

Guo A (2010) CST Curation Set: 6268; Year: 2010; Biosample/Treatment: cell line, 293/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

47

Guo A (2010) CST Curation Set: 6270; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

48

Guo A (2010) CST Curation Set: 6271; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

49

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

50

Possemato A (2010) CST Curation Set: 9349; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V)
Curated Info

51

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

52

Possemato A (2010) CST Curation Set: 9156; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

53

Possemato A (2010) CST Curation Set: 9151; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

54

Tucker M (2010) CST Curation Set: 8913; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

55

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

56

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

57

Olson FJ, Ludowyke RI, Karlsson NG (2009) Discovery and identification of serine and threonine phosphorylated proteins in activated mast cells: implications for regulation of protein synthesis in the rat basophilic leukemia mast cell line RBL-2H3. J Proteome Res 8, 3068-77
19317463   Curated Info

58

Possemato A (2009) CST Curation Set: 6454; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

59

Possemato A (2009) CST Curation Set: 6455; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

60

Possemato A (2009) CST Curation Set: 6450; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/control; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

61

Possemato A (2009) CST Curation Set: 6438; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

62

Guo A (2009) CST Curation Set: 6256; Year: 2010; Biosample/Treatment: cell line, 293/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

63

Rose AJ, et al. (2009) Skeletal muscle eEF2 and 4EBP1 phosphorylation during endurance exercise is dependent on intensity and muscle fiber type. Am J Physiol Regul Integr Comp Physiol 296, R326-33
19036825   Curated Info

64

Possemato A (2008) CST Curation Set: 5316; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

65

Greenhaff PL, et al. (2008) Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. Am J Physiol Endocrinol Metab 295, E595-604
18577697   Curated Info

66

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

67

McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80
18212344   Curated Info

68

Smith EM, Proud CG (2008) cdc2-cyclin B regulates eEF2 kinase activity in a cell cycle- and amino acid-dependent manner. EMBO J 27, 1005-16
18337751   Curated Info

69

Rikova K (2008) CST Curation Set: 4103; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

70

Rikova K (2008) CST Curation Set: 4106; Year: 2008; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

71

Zhou J (2008) CST Curation Set: 3676; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

72

Tosca L, Uzbekova S, Chabrolle C, Dupont J (2007) Possible role of 5'AMP-activated protein kinase in the metformin-mediated arrest of bovine oocytes at the germinal vesicle stage during in vitro maturation. Biol Reprod 77, 452-65
17567959   Curated Info

73

Guo A (2007) CST Curation Set: 2774; Year: 2007; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621
Curated Info

74

Moritz A (2007) CST Curation Set: 2779; Year: 2007; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

75

Moritz A (2007) CST Curation Set: 2762; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621
Curated Info

76

Moritz A (2007) CST Curation Set: 2764; Year: 2007; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621
Curated Info

77

Moritz A (2007) CST Curation Set: 2766; Year: 2007; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621
Curated Info

78

Possemato A (2007) CST Curation Set: 2720; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621
Curated Info

79

Possemato A (2007) CST Curation Set: 2654; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

80

Possemato A (2007) CST Curation Set: 2655; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

81

Molina H, et al. (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199-204
17287340   Curated Info

82

Dreyer HC, et al. (2006) Resistance exercise increases AMPK activity and reduces 4E-BP1 phosphorylation and protein synthesis in human skeletal muscle. J Physiol 576, 613-24
16873412   Curated Info

83

Roberts EC, et al. (2006) Identification of G2/M targets for the MAP kinase pathway by functional proteomics. Proteomics 6, 4541-53
16858730   Curated Info

84

Kim JE, Tannenbaum SR, White FM (2005) Global phosphoproteome of HT-29 human colon adenocarcinoma cells. J Proteome Res 4, 1339-46
16083285   Curated Info

85

Browne GJ, Proud CG (2004) A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 24, 2986-97
15024086   Curated Info

86

Browne GJ, Finn SG, Proud CG (2004) Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem 279, 12220-31
14709557   Curated Info

87

Knebel A, Haydon CE, Morrice N, Cohen P (2002) Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways. Biochem J 367, 525-32
12171600   Curated Info